Key trials and players in the Gene / Cell Therapy landscape

At LucidQuest (www.lqventures.com) we spend quite a bit of time conducting research in the Gene and Cell therapy space, focusing on better understanding the next key players and developments. 

We updated a brief analysis we conducted a few years ago (see here), looking into Phase II/III and Phase III trials (as found in the clinicaltrials.gov database) which employed Cell or Gene Therapy approaches. For the this latest analysis, we included Phase II, Phase II/III and Phase III trials which are industry-sponsored and are active (some are yet to begin recruitment).

Some points to note

• >25,000 patiens are being enrolled in these late stage Gene / Cell therapy studies (with ~12,000 patients recruited in VivaTech's shoulder, hip and knee OA pain trials!).
• The number of targets and diseases which are being investigated has increased significantly over the past five years. See below for the top indications under study.

• And the number of companies that are now involved in Cell and Gene Therapy trials has also increased, with established Pharma players also jumping into the space (see below).

If you would like to gain more insights around these trials or on how to remain competitive in the Cell and Gene Therapy space, feel free to send us a message to [email protected] and we will be in touch for an informal discussion.

We are also running the the leading Gene and Cell Therapy Group on LinkedIn, so don't forget to join!

Finally, you can always find more about LucidQuest at www.lqventures.com or by following our LinkedIn page.